Role of erythropoietin in the treatment of Alzheimer's disease: the story so far.

Autor:	Kalluru PKR; Sri Venkateswara Medical College, Puducherry., Bhavanthi S; General Medicine, Nizamabad Government Medical College, Nizamabad., Vashist S; General Medicine, NC Medical College and Hospital, Haryana., Gopavaram RR; Internal Medicine, Dnipropetrovsk Medical Academy of Health Ministry of Ukraine, Dnipro, Ukraine., Mamilla M; Sri Venkateswara Medical College, Puducherry., Sharma S; Internal Medicine, Dnipropetrovsk Medical Academy of Health Ministry of Ukraine, Dnipro, Ukraine., Gundoji CR; General Medicine, Nizamabad Government Medical College, Nizamabad., Goguri SR; Chalmeda Anand Rao Institute of Medical Sciences, Telangana, India.
Jazyk:	angličtina
Zdroj:	Annals of medicine and surgery (2012) [Ann Med Surg (Lond)] 2024 May 01; Vol. 86 (6), pp. 3608-3614. Date of Electronic Publication: 2024 May 01 (Print Publication: 2024).
DOI:	10.1097/MS9.0000000000002113
Abstrakt:	This review aims to explore the potential of erythropoietin, a glycopeptide hormone, as a treatment option for Alzheimer's disease, which is the commonest cause of dementia. Despite years of focus and research, therapeutic options for Alzheimer's disease are not yet completely satisfactory. And as people age, they are likely to develop Alzheimer's Disease, further pressuring the healthcare system. So, it is definite to develop treatment options that meet superior outcomes with minimal negative effects. A comprehensive review of the literature was conducted in PubMed and Google Scholar using a combination of keywords, including Alzheimer's disease, dementia, erythropoietin, and neuroprotection. Search results were assessed for relevance before using the data for this study. The beneficial implications of erythropoietin as a therapeutic option have been explored, along with the side effects and mechanisms of erythropoietin in Alzheimer's disease. Overall, the authors' review indicates that erythropoietin presents a promising avenue for mitigating the progression of Alzheimer's disease, with minimal associated side effects. Competing Interests: None of the authors have conflicts of interest to disclose.Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu